1. Trojsi F, Christidi F, Migliaccio R, Santamaría-García H, Santangelo G. Behavioural and cognitive changes in neurodegenerative diseases and brain injury. Behav Neurol 2018;2018:4935915.
2. Do Carmo S, Cuello AC. Modeling Alzheimer’s disease in transgenic rats. Mol Neurodegeneration 2013; 8:37-60.
3. Schain M, Kreisl WC. Neuroinflammation in neurodegenerative disorders-a review. Curr Neurol Neurosci Rep 2017; 17:25-35.
4. Tanaka T, Kai S, Matsuyama T, Adachi T, Fukuda K, Hirota K. General anesthetics inhibit LPS-induced IL-1beta expression in glial cells. PLoS One 2013; 11;8:e82930.
5. Trenova A, Slavov G, Miteva L, Manova M, Stanilova S. Immunological aspects of cognitive functioning: highlights on the role of the cytokines. TJS 2016; 4:391-397.
6. Lobo-Silva D, Carriche GM, Castro AG, Roque S, Saraiva M. Balancing the immune response in the brain: IL-10 and its regulation. J Neuroinflammation 2016; 13:297-324.
7. Farbood Y, Sarkaki A, Dolatshahi M, Taqhi Mansouri SM, Khodadadi A. Ellagic acid protects the brain against 6-hydroxydopamine induced neuroinflammation in a rat model of Parkinson’s disease. Basic Clin Neurosci 2015; 6:83-89.
8. Baune BT, Wiede F, Braun A, Golledge J, Arolt V, Koerner H. Cognitive dysfunction in mice deficient for TNF- and its receptors. Am J Med Genet B Neuropsychiatr Genet 2008; 5;147B:1056-1064.
9. Alam Q, Alam MZ, Mushtaq G, Damanhouri GA, Rasool M, Kamal MA, et al. Inflammatory process in Alzheimer’s and Parkinson’s diseases: central role of cytokines. Curr Pharm Des 2016; 22:541-548.
10. Wyss-Coray T. TGF-β Pathway as a potential target in neurodegeneration and Alzheimer’s. Curr Alzheimer Res 2006; 3:191-195.
11. Caraci F, Gulisano W, Guida CA, Impellizzeri AA, Drago F, Puzzo D, et al. A key role for TGF-β1 in hippocampal synaptic plasticity and memory. Sci Rep 2015; 5:11252-11261.
12. Norden DM, Fenn AM, Dugan A, Godbout JP. TGFβ produced by IL-10 redirected astrocytes attenuates microglial activation. Glia 2014; 62:881-895.
13. Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth Factors 2004; 22:123-131.
14. Zhao J, Bi W, Xiao S, Lan X, Cheng X, Zhang J et al. Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice. Sci Rep 2019; 9: 5790-5802.
15. Tokunaga N, Choudhury ME, Nishikawa N, Nagai M, Tujii T, Iwaki H, et al. Pramipexole upregulates dopamine receptor D2 and D3 expression in rat striatum. J Pharmacol Sci 2012; 120: 133-137.
16. Lieberknecht V, Junqueira SC, Cunha MP, Barbosa TA, de Souza LF, Coelho IS, et al. Pramipexole, a dopamine d2/d3 receptor-preferring agonist, prevents experimental autoimmune encephalomyelitis development in mice. Mol Neurobiol 2017; 54:1033-1045.
17. Salmani H, Hosseini M, Baghcheghi Y, Moradi-Marjaneh R, Mokhtari-Zaer A. Losartan modulates brain inflammation and improves mood disorders and memory impairment induced by innate immune activation: The role of PPAR-γ activation. Cytokine 2020;125:154860.
18. Ghafouri S, Fathollahi Y, Javan M, Shojaei A, Asgari A, Mirnajafi-Zadeh J. Effect of low frequency stimulation on impaired spontaneous alternation behavior of kindled rats in Y-maze test. Epilepsy Res 2016;126:37-44.
19.Ranjbar H, Aghaei I, Moosazadeh M, Shabani M. Angiotensin II type 1 receptor blocker losartan attenuates locomotor, anxiety-like behavior, and passive avoidance learning deficits in a sub-chronic stress model. Iran J Basic Med Sci. 2018;21:856-862.
20. Hörtnagl H, Berger ML, Sperk G, Pifl C. Regional heterogeneity in the distribution of neurotransmitter markers in the rat hippocampus. Neuroscience. 1991;45:261-272.
21. Shathiswaran NA, Vijayapandi P, Zazali A, Habsah AK. Deoxyelephantopin ameliorates lipopolysaccharides (LPS)-induced memory impairments in rats: Evidence for its anti-neuroinflammatory properties. Life Sci 2018; 206:45-60.
22. Broadbent NJ, Gaskin S, Squire LR, Clark RE. Object recognition memory and the rodent hippocampus. Learn Mem 2009; 17:5-11.
23. Winters BD, Saksida LM, Bussey TJ. Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval. Neurosci Biobehav Rev 2008; 32: 1055-1070.
24. Noble EE, Mavanji V, Little MR, Billington CJ, Kotz CM, Wang C. Exercise reduces diet-induced cognitive decline and increases hippocampal brain-derived neurotrophic factor in CA3 neurons. Neurobiol Learn Mem 2014; 114:40-50.
25. Edelmann E, Lessmann V. Dopaminergic innervation and modulation of hippocampal networks. Cell Tissue Res 2018; 373:711-727.
26. Izquierdo I, Bevilaqua LRM, Rossato JI, Bonini JS, Medina JH, Cammartota M. Different molecular cascades in different sites of the brain control memory consolidation. Trends Neurosci 2006; 29:496-505.
27. Albani SH, McHail DG, Dumas TC. Developmental studies of the hippocampus and hippocampal-dependent behaviors: insights from interdisciplinary studies and tips for new investigators. Neurosci Biobehav Rev 2014; 43:183–190.
28. Onaolapo OJ, Onaolapo AY, Mosaku TJ, Akanji OO, Abiodun OR. Elevated plus maze and Y-maze behavioral effects of subchronic, oral low dose monosodium glutamate in Swiss albino mice. IOSR Journal of Pharmacy and Biological Sciences 2012; 3:21-27.
29. Yang ST, Shi Y, Wang Q, Peng JY, Li BM. Neuronal representation of working memory in the medial prefrontal cortex of rats. Mol Brain 2014; 7:61-73.
30. Beier EE, Neal M, Alam G, Edler M, Wu LJ, Richardson JR. Alternative microglial activation is associated with cessation of progressive dopamine neuron loss in mice systemically administered lipopolysaccharide. Neurobiol Dis 2017; 108:115-127.
31. Arimoto T, Choi DY, Lu X, Liu M, Nguyen XV, Zheng N, et al. Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol Aging 2007; 28:894-906.
32. Kawano M, Takagi R, Saika K, Matsui M, Matsushita S. Dopamine regulates cytokine secretion during innate and adaptive immune responses. Int Immunol 2018; 30:591–606.
33. Arreola R, Alvarez-Herrera S, Pérez-Sánchez G, Becerril-Villanueva E, Cruz-Fuentes C, Flores-Gutierrez EO, et al. Immunomodulatory effects mediated by dopamine. J Immunol Res 2016; 2016:3160486.
34. Richwine AF, Sparkman NL, Dilger RN, Buchanan JB, Johnson RW. Cognitive deficits in interleukin-10-deficient mice after peripheral injection of lipopolysaccharide. Brain Behav Immun 2009; 23:794-802.
35.Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007; 55:453-462.
36. Lapchak PA, Araujo DM, Hefti F. Systemic interleukin-1 beta decreases brain-derived neurotrophic factor messenger RNA expression in the rat hippocampal formation. Neuroscience 1993; 53:297-301.
37. Guan Z, Fang J. Peripheral immune activation by lipopolysaccharide decreases neurotrophins in the cortex and hippocampus in rats. Brain Behav Immun 2006; 20:64-71.
38. Zhang JC, Yao W, Hashimoto K. Brain-derived neurotrophic factor (BDNF)-TrkB signaling in inflammation-related depression and potential therapeutic targets. Curr Neuropharmacol 2016; 14:721-731.
39. Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 2011; 14:347-353.
40. Du F, Li R, Huang Y, Li X, Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 2005; 22:2422–2430.
41. Berghauzen-Maciejewska K, Wardas J, Kosmowska B, Głowacka U, Kuter K, Ossowska K. Alterations of BDNF and trkB mRNA expression in the 6-hydroxydopamine-induced model of preclinical stages of Parkinson’s disease: an influence of chronic pramipexole in rats. PLoS One 2015; 10:e0117698.
42. Wegrzyniaka BH, Dobrzanski P, Stoehrc JD, Wenka GL. Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer’s disease. Brain Res 1998; 780:294-303.
43. Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW, et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation 2008; 5:37-50.